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Background: Postural Orthostatic Tachycardia Syndrome (POTS) is a cardiovascular
autonomic disorder characterized by orthostatic intolerance and high prevalence
among young women. The etiology of POTS is uncertain, though autoimmunity and
inflammation may play an important role. We aimed to identify novel inflammatory
biomarkers associated with POTS.
Methods and Results: In the Syncope Study of Unselected Population in Malmö
(SYSTEMA) cohort, we identified 396 patients (age range, 15–50 years) with either
POTS (n = 113) or normal haemodynamic response during passive head-up-tilt test
(n = 283). Blood samples were analyzed using antibody-based Proximity Extension
Assay technique simultaneously measuring 57 inflammatory protein biomarkers. The
discovery algorithm was a sequential two-step process of biomarker signature
identification by supervised, multivariate, principal component analysis and verification
by univariate ANOVA with Bonferroni correction. POTS patients were younger (26 vs.
31 years; p < 0.001) and there was no significant difference in sex distribution (74% vs.
67% females, p = 0.24). PCA and Bonferroni-adjusted ANOVA identified proconvertase
furin as the most robust biomarker signature for POTS. Plasma level of proconvertase
furin was lower (6.38 vs. 6.58 of normalized protein expression units (NPX); p < 0.001 in
POTS, compared with the reference group. Proconvertase furin met Bonferroni-adjusted
significance criteria in both uni- and multivariable regression analyses.
Conclusion: Patients with POTS have lower plasma level of proconvertase furin
compared with individuals with normal postural hemodynamic response. This finding
suggests the presence of a specific autoimmune trait with disruption of immune
peripheral tolerance in this hitherto unexplained condition. Further studies are needed
for external validation of our results.
Keywords: postural orthostatic tachycardia syndrome, inflammation, biomarkers, proteomics,
proconvertase furin
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INTRODUCTION
Postural orthostatic tachycardia syndrome (POTS) is a complex
condition featuring signs of autonomic dysfunction with both
cardiovascular and non-cardiovascular symptoms (Benarroch,
2012). Although typically multi-symptomatic, POTS is by
definition characterized by an abnormally increased heart rate
upon standing and symptoms of orthostatic intolerance without
significant blood pressure decrease (Sheldon et al., 2015). The
syndrome affects predominantly young women (70–80%) with
increasing incidence in developed countries, but its etiology
has not been established (Sheldon et al., 2015; Brinth et al.,
2018). Aside from orthostatic intolerance, patient frequently
report headache, palpitations, brain fog and fatigue, which is
believed to be a consequence of both hyperadrenergic state and
decreased blood flow to the brain (Benarroch, 2012; Li et al., 2014;
Arnold et al., 2018).
As etiology of POTS is still unknown, effective treatment
for this syndrome is yet to be developed. Therapeutic options
available today have modest efficacy and focus only on alleviating
symptoms, thus, further research is mandatory. It has been
observed that some patients develop POTS after experiencing a
febrile illness, presumably viral (Grubb, 2008; Li et al., 2014).
This has led to the hypothesis of an autoimmune-mediated
etiology of POTS, and recent case series of POTS following
immune triggers like infection or vaccination (Blitshteyn, 2015;
Brinth et al., 2015; Watari et al., 2018) support this hypothesis.
It has already been established that activating autoantibodies
(AAb) to the α1-adrenergic (α1AR), β1/2-adrenergic receptors
(β1/2AR), and angiotensin-receptor type 1 can be found in serum
from POTS patients but not in controls (Fedorowski et al.,
2017; Yu et al., 2018). In current knowledge of the presence of
autoantibodies and possible immunological triggers, exploration
of expression of inflammatory mediators in POTS is required,
both as a potential diagnostic tool and therapeutic target in this
ill-understood condition for which there is no effective treatment.
In this study, we sought to discover inflammatory biomarkers
associated with POTS in order to identify a signature, which
could potentially be useful to understand the pathophysiology
underlying the syndrome. We applied a new method of multiple-
protein screening using oligonucleotide-labeled antibodies
against selected serum proteins.
MATERIALS AND METHODS
Study Population
The study was performed between September 2008 and May
2014 on a series of 545 consecutive patients aged 15–50 years
enrolled in the ongoing Syncope Study of Unselected Population
in Malmö (SYSTEMA) (Fedorowski et al., 2010). The age
range was based on previous epidemiological studies on
POTS incidence (Goodman, 2018). The recruited patients were
referred to the tertiary syncope investigation unit at Skåne
University Hospital in Malmö from primary and outpatient
care clinics as well as hospitals in the southern region of
Sweden due to unexplained syncope and/or symptoms of
orthostatic intolerance. The referred patient underwent an initial
diagnostic workup, typically including clinical history, resting,
exercise and ambulatory prolonged electrocardiogram (Holter-
ECG), transthoracic echocardiography, coronary and pulmonary
angiography, brain imaging and encephalography, if requested
by the referring physician. In the Syncope Unit, the patients
were investigated by cardiovascular autonomic tests including
head-up tilt testing (HUT), according to the European syncope
guidelines available during this period (Moya et al., 2009). Blood
samples were collected during the examination. The final study
population included 113 POTS individuals and 283 controls with
normal hemodynamic response during HUT as well as without
prevalent cardiovascular disease (ischemic heart disease, heart
failure, and stroke) or hypertension.
The study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by The Regional
Ethical Review Board of Lund University (No 82/2008). All
patients gave their written informed consent.
The PICO model was as follows: patients with unexplained
syncope or orthostatic intolerance (Population), blood samples
and HUT (Intervention), POTS patients versus controls
(Comparison), and targeted protein biomarker discovery and
haemodynamic response (Outcome).
Examination Protocol
Patients discontinued cardiovascular drugs 48 h before the test,
fasted for 2 h prior to examination and were allowed to drink
water at will. The past medical history was explored using a
standard study questionnaire. The patients were placed on a tilt
table and a venous cannula was inserted in the forearm after
which a rest period for at least 10 min was allowed before blood
samples were collected through the cannula. As soon as the
haemodynamic parameters were stable, a standard 70◦HUT was
carried out according to the Italian protocol recommended by
ESC (Bartoletti et al., 2000; Moya et al., 2009). Beat-to-beat blood
pressure and ECG were monitored continuously by a validated
non-invasive photoplethysmographic method (Nexfin monitor;
BMEYE, Amsterdam, Netherlands) with a wrist unit and finger
cuff of appropriate size (Eeftinck Schattenkerk et al., 2009).
POTS was defined as reproduction of symptoms of orthostatic
intolerance (lightheadedness, dizziness, or discomfort) along
with heart rate increase >30 beats/min or sinus tachycardia
>120 beats/min during first 10 min of HUT; or increase
>40 beats/min for those under 18 years of age, with a history of
orthostatic intolerance for at least 6 months (Sheldon et al., 2015).
Multiplex Protein Analysis
Plasma biomarkers were measured from supine blood samples
(total volume: 30 ml) that had been first centrifuged, then
stored as 16 × 250 µL aliquots of EDTA plasma in plastic
thermotubes, and frozen at −80◦C. For biomarker analysis, the
samples were thawed and examined by the Proximity Extension
Assay technique using the Olink Proteomics Proseek Multiplex
Oncology I v1 96 × 96 reagents kit, which simultaneously
measures 57 inflammatory and cancer-related human protein
biomarkers in plasma (Supplementary Table S1). Briefly, a pair
of oligonucleotide-labeled antibodies, Proseek probes, binds to
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the target protein in the plasma sample. When the two Proseek
probes are in close proximity, a new polymerase-chain reaction
(PCR) target sequence is formed by a proximity-dependent DNA
polymerization event. This complex is subsequently detected
and quantified using standard real-time PCR. The generated
Normalised Protein Expression (NPX) unit is on a log2 scale,
which means that a larger number represents a higher protein
level in the sample. Additional information concerning limit of
detection, reproducibility and validation is available at the Olink
Proteomics website1.
Statistical Analysis
For the statistical analyses, patients with available proteomics
data and definitive diagnosis of POTS (n = 113) or normal
hemodynamic response during HUT (n = 283), i.e., without
orthostatic hypotension (Moya et al., 2009; Freeman et al., 2011)
and abnormal postural tachycardia, as well as without prevalent
cardiovascular disease (ischemic heart disease, heart failure,
and stroke) or hypertension were selected. Missing data was
imputed with multiple imputations by chained equations (MICE)
approach to create 10 complete datasets. We used predictive
mean matching for continuous variables, logistic regression
for binary variables, and polytomous regression for categorical
variables. All covariates were included in the imputation models.
The maximum iteration was set at 20 and convergence was
confirmed by visual examination of trace plots. The main
characteristics of study population were calculated as mean and
standard deviation for continuous variables and as percentages
for categorical variables, both for the total study population, and
separately for POTS-positive and -negative patients.
The discovery algorithm for the identification of potentially
relevant biomarkers associated with the presence of POTS
was a sequential two-step process of (i) biomarker signature
identification by a supervised, multivariate, principal component
analysis, and (ii) verification by univariate ANOVA with
Bonferroni correction. This method has been previously
validated in our hands (Johansson et al., 2018a,b).
After defining a minimal call rate <75%, we screened
the biomarker panel through supervised principal component
analysis, according to the algorithm first described by Hastie et al.
(2013), which includes the following steps:
(1) For each biomarker, compute the standardized univariate
logistic regression coefficient which represents the effect
size for the outcome (presence or absence of POTS).
(2) Using an arbitrary effect size threshold θ from the list
0 ≤ θ1 < θ2 < · · · < θK.
(a) Form a reduced data matrix consisting of only
those biomarkers whose univariate coefficient
exceeds θ in absolute value, and compute the
principal components of this matrix.
(b) Use these principal components in a multivariate
logistic regression model to predict POTS status.
(3) Select the threshold θ which gives the best predictive
accuracy by 10-fold cross-validation.
1http://www.olink.com/products/document-download-center
Thereafter, for the verification of the selected biomarkers we
applied a conservative univariate ANOVA approach, using a
Bonferroni-adjusted significance level of p < 0.05/number of
PCA-selected biomarkers. Box plots were generated to display the
distribution of biomarker levels between groups.
Furthermore, we performed both univariate and multivariate
ordinary least square linear regression and logistic regression
models for bivariate correlation between plasma level of selected
biomarkers and maximum orthostatic heart rate change (1HR)
or POTS status, respectively. In multivariate regression models
we adjusted for age and sex. Finally, we performed a quantile-
regression analysis in order to identify differing relationships
at different quartiles of HR changes during HUT. The mean
estimates and standard errors of the beta-coefficients for the
imputed datasets were combined with Rubin’s rules (Rubin,
1987). Statistical analyses were carried out using IBM SPSS
Statistics version 25 (SPSS Inc., Chicago, IL, United States) and




The dataset consisted of 396 patients (113 POTS and
283 controls). Baseline characteristics of the study population
by POTS status are shown in Table 1. There was no significant
difference in characteristics between the whole cohort and
complete cases without missing data (Supplementary Table S2).
Since the principal component analysis requires pairwise
complete data, we did not include markers with high missingness,
i.e., above 35%. This filter resulted in removal of 9 biomarkers:
erythropoietin, interleukin-2, interferon-gamma, tumor necrosis
factor, carcinoembryonic antigen, vascular endothelial statin,
lipopolysaccharide-induced tumor necrosis factor (TNF)-alpha
factor, myeloid differentiation primary response protein, MHC
class I polypeptide-related sequence A. Univariate logistic
TABLE 1 | Baseline characteristics of the study population.
Characteristic POTS− (n = 283) POTS+ (n = 113) P-value
Age 31.47 (9.85) 26.27 (8.41) <0.001
Female sex, n (%) 189 (66.8) 83 (73.5) 0.241
BMI, Kg/m2 24.33 (4.14) 22.69 (3.50) <0.001
SBP supine, mmHg 120.07 (14.16) 120.41 (14.20) 0.833
DBP supine, mmHg 69.98 (8.21) 70.22 (8.22) 0.788
HR supine, bpm 68.86 (11.87) 71.13 (11.57) 0.084
SBP HUT min, mmHg 112.34 (13.35) 107.58 (16.24) 0.003
DBP HUT min, mmHg 71.83 (9.11) 72.46 (10.58) 0.552
HR HUT max, bpm 84.77 (13.77) 112.41 (15.63) <0.001
Smoking, n (%) 58 (20.5) 16 (14.2) 0.188
P-values for differences between the groups are shown as mean and SD for
continuous variables and as percentages for categorical variables; DBP, diastolic
blood pressure; HR, heart rate; HUT min/max, lowest/highest value during
passive head-up tilt test; IHD, ischemic heart disease; POTS, postural orthostatic
tachycardia syndrome; SBP, systolic blood pressure.
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FIGURE 1 | The plasma levels of proconvertase furin, expressed on a log2 scale, presented in relation to POTS status. Data are shown as a box and whisker plot
with median in the box and the whiskers representing the 5th and 95th percentiles in relation to plasmatic biomarker levels.
regression was performed for each of the 48 biomarkers.
Heatmap representation of the data showing the hierarchical
clustering of the 48 biomarkers by POTS status is shown in
Supplementary Figure S2.
The regression coefficients were then standardized by
dividing the coefficient with its standard error. All possible
thresholds (Standardized coefficient (θ) ranging from minimum
to maximum with 0.05 increments) were used to select groups
of biomarkers and construct principal components (PCs). The
outcome variable (POTS status) was then regressed onto the
1st two PCs from each group of biomarkers using the binomial
link function. This step identified the group of biomarkers
which gave the best classification accuracy. The threshold that
gave the best classification accuracy (POTS+ vs. controls)
was selected by ten-fold cross-validation. The following four
biomarkers reached this threshold: carbonic anhydrase IX;
receptor tyrosine-protein kinase erbB-2; Fms-related tyrosine
kinase 3 ligand; and proconvertase furin.
Biomarker Verification
All PCA-selected biomarkers except carbonic anhydrase
IX differed significantly in pairwise comparison, but only
proconvertase furin attained significance after Bonferroni
correction (Figure 1 and Table 2). In multivariate regression
analysis both POTS status and maximum orthostatic 1HR were
significantly associated with proconvertase furin (Tables 3, 4).
Quantile regression analyses investigating the relationships
between proconvertase furin and the quartiles of 1HR did
not reveal any obvious threshold effect or step function
(Supplementary Figure S1). Finally, tertiles of proconvertase
furin were inversely proportional to duration of symptoms
(ANOVA, p-value for multiple comparisons = 0.021), defined
as the time elapsed from the first symptom manifestation
(presyncope or syncope) in patient’s history and the time of
diagnostic examination (HUT).
DISCUSSION
In this study, we explored the inflammatory proteomic signature
of POTS in order to elucidate pathophysiological mechanisms
underlying this particular phenotype of cardiovascular
autonomic dysfunction. We demonstrated that POTS is
TABLE 2 | High throughput multiplex analysis biomarkers selected by supervised
multivariate principal component analysis.
Biomarker POTS+ (n = 113) POTS− (n = 283) P-value
FUR 6.38 (0.05) 6.58 (0.03) 0.000276∗
CAIX 1.53 (0.09) 1.73 (0.06) 0.050109
Flt3L 7.76 (0.05) 7.89 (0.03) 0.012979
ErbB2HER2 7.79 (0.04) 7.92 (0.03) 0.026045
Plasma concentrations of the assessed proteins are expressed on a log2-
scale. Inter-group differences were assessed using analysis of variance method.
∗Bonferroni-corrected significant values (p < 0.012). CAIX, Carbonic anhydrase IX;
ErbB2HER2, Receptor tyrosine-protein kinase erbB-2; Flt3L, Fms-related tyrosine
kinase 3 ligand; FUR, furin.
TABLE 3 | Relationship between POTS status and selected biomarker in
univariate and multivariate regression.
Biomarker Univariate Multivariate∗
OR 95% CI P-value OR 95% CI P-value
FUR 0.81 0.73–0.92 <0.001 0.86 0.77–0.96 0.009
∗Adjusted for age, sex.
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TABLE 4 | Relationship between changes in heart rate during head-up tilt test and
selected biomarker in univariate and multivariate regression.
Biomarker Univariate Multivariate∗
β 95% CI P-value β 95% CI P-value
FUR −7.0 −10.6 to −3.38 <0.001 −4.2 −7.9 to −0.5 0.03
∗Adjusted for age, sex.
associated with lower circulating levels of proprotein convertases
subtilisin/kexin type (PCSK)-3, i.e., proconvertase furin.
Interestingly, the earlier the disease starts, the lower the
proconvertase furin level.
Our findings confirm and further expand the growing body
of evidence pointing to an immune dysregulation as the primary
pathophysiological mechanism underlying POTS. However, it is
noteworthy that pro-inflammatory cytokines and chemokines,
i.e., interleukin-7, interleukin-12 and CXC motif chemokine 13,
associated with systemic inflammatory diseases such as systemic
lupus erythromatosus or rheumatoid arthritis were not increased
among POTS-positive patients.
The Role of Immune System in POTS
The presence of immunoglobulins activating and modulating
multiple G-protein coupled receptors (GPCR) linked to the
autonomic nervous system has been previously demonstrated
in POTS patients (Fedorowski et al., 2017; Yu et al., 2018),
as well as their ability to alter dose-response to the natural
ligands in vitro. Patients suffering from POTS are most frequently
young females of childbearing age (Li et al., 2014). Its onset is
occasionally preceded by or associated with a viral-like illness or
post vaccination which leads to the suspicion that autoimmunity
may have an important role in these patients (Li et al., 2014;
Brinth et al., 2015). Studies performed recently indicate that
patients with POTS have higher prevalence of autoimmune
markers and co-morbid autoimmune disorders compared with
the general population (Blitshteyn, 2015). Accordingly, nearly
one fourth of patients with POTS have positive ANA and one in
three have some type of autoimmune markers (Blitshteyn, 2015).
Moreover, a high proportion of POTS patients are seropositive
for circulating antiganglionic acetylcholine receptor antibodies
(Watari et al., 2018).
Finally, presence of antibodies against adrenergic and
cholinergic receptors were confirmed in patients suffering from
POTS in a number of studies, which could explain the adrenergic-
related symptoms including exaggerated heart rate during
orthostatic challenge (Ruzieh et al., 2017).
Proconvertase Furin
Proconvertase furin is one of seven proprotein convertase family
members that promote proteolytic maturation of proproteins
(Barr et al., 1991). Ubiquitously expressed it has been reported
to process a variety of secreted factors including cytokines
and chemokines such as anti-inflammatory transforming growth
factor (TGF)-β1 and secreted TNF-family receptors (Loetscher
et al., 1990). Interestingly, previous evidence has suggested that
proconvertase furin inhibition may result in a breakdown of
peripheral tolerance (Pesu et al., 2008) and development of
systemic autoimmune disease (Lisi et al., 2010). In experimental
models of rheumatoid arthritis, exogenous proconvertase furin
has been successfully used to harness autoimmunity (Lin et al.,
2012). This is consistent also with recent findings reporting
the association between high proconvertase furin levels and
lower systemic activity disease in primary Sjögren’s syndrome
(Ranta et al., 2018). Considering that proconvertase furin
appears to be involved in maintaining immune homeostasis,
it is important to note that only one POTS patient in our
series had overt autoimmune comorbidity. Consequently, we
may reasonably exclude that we have tracked down the effect
of parallel autoimmune disorders on proconvertase furin in
POTS population.
While the exact source of circulating levels of this protein
in POTS patients remains unclear, we speculate that they may
reflect a so far undetected viral activity. Indeed, cleavage of
the human papilloma virus capsid protein L2 by proconvertase
furin is necessary for infection (Richards et al., 2006), while the
HIV-1 protein Nef is known to bind furin in order to sequester
human leukocyte antigen-family receptors in the trans-Golgi
network (Piguet et al., 2000). Presumably as a countermeasure,
proconvertase furin is down-regulated during inflammation in
a suppressor of cytokine signaling (Sox)-dependent manner
(Guimont et al., 2007).
Taken together, further studies are warranted to confirm these
findings in independent populations before proconvertase furin
can be considered as an objective serum marker of POTS.
Limitations
There is a number of important limitations that should be
addressed. Firstly, inflammatory biomarkers have been sampled
only at the time of POTS diagnosis; the lack of serial
measurements prevent us to understand whether the alterations
seen are a cause or a consequence of POTS, and whether there is
any temporal correlation between proconvertase furin levels and
the progression of the disease.
Secondly, this is a hypothesis-generating study aimed to
discover alternative pathophysiological pathways involved in
POTS, requiring external validation in another cohort.
Thirdly, data on important pro-inflammatory cytokines like
IL-2, TNF-a, IFN is lacking.
Finally, in order to rule-out possible false positive signals,
our findings should be verified and validated with alternative
technologies enabling as much sensitive and robust detection and
quantification of biomarkers; However, the use of a proximity
assay with the requirement for a dual binding event which
ensures minimal background signal, and the robust discovery
algorithm, based on a sequential two-step process including
principal component analysis and a very strict Bonferroni
correction, would make a false positive result less likely.
CONCLUSION
Proteomic profiling by proximity extension technique
revealed an inflammation-specific biomarker fingerprint in
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POTS patients. Circulating levels of proconvertase furin are
downregulated in POTS suggesting a complex and intriguing
interplay between autoimmune activity and cardiovascular
autonomic dysfunction.
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FIGURE S1 | Heatmap visualization of the proteomics data showing the
hierarchical clustering of 48 biomarkers by POTS status.
FIGURE S2 | Quantile regression analysis. Furin regressed on 25th, 50th and 75th
quantiles of delta HR max. The x axis is the quantile of delta HR max (black dots in
the plots represent the regression coefficient at 0.25, 0.5 (median) and 0.75). The
gray bands are the 95% CI of the quantile regression coefficient. The horizontal
red and the two horizontal dotted lines are the ordinary least square (OLS) linear
regression lines. What you can see here is that 95% CI of the coefficients from
quantile regression overlaps widely with OLS lines indicating that Furin does not
have differing effects on different quantiles of delta HR max.
TABLE S1 | Immuno-oncology panel: biomarker list.
TABLE S2 | Comparison of baseline characteristics between the whole cohort
and complete cases without missing data.
REFERENCES
Arnold, A. C., Ng, J., and Raj, S. R. (2018). Postural tachycardia
syndrome - diagnosis, physiology, and prognosis. Auton. Neurosci. 215,
3–11. doi: 10.1016/j.autneu.2018.02.005
Barr, P. J., Mason, O. B., Landsberg, K. E., Wong, P. A., Kiefer, M. C., and Brake,
A. J. (1991). cDNA and gene structure for a human subtilisin-like protease with
cleavage specificity for paired basic amino acid residues. DNA Cell Biol. 10,
319–328. doi: 10.1089/dna.1991.10.319
Bartoletti, A., Alboni, P., Ammirati, F., Brignole, M., Del Rosso, A., Foglia
Manzillo, G., et al. (2000). ‘The Italian Protocol’: a simplified head-up tilt testing
potentiated with oral nitroglycerin to assess patients with unexplained syncope.
Europace 2, 339–342. doi: 10.1053/eupc.2000.0125
Benarroch, E. E. (2012). Postural tachycardia syndrome: a heterogeneous and
multifactorial disorder. Mayo Clin. Proc. 87, 1214–1225. doi: 10.1016/j.mayocp.
2012.08.013
Blitshteyn, S. (2015). Autoimmune markers and autoimmune disorders in patients
with postural tachycardia syndrome (POTS). Lupus 24, 1364–1369. doi: 10.
1177/0961203315587566
Brinth, L., Pors, K., Spahic, J. M., Sutton, R., Fedorowski, A., and Mehlsen, J. (2018).
Postural Orthostatic Tachycardia Syndrome (POTS) in denmark: increasingly
recognized or new epidemic? Auton. Neurosci. 213, 92–95. doi: 10.1016/j.
autneu.2018.03.001
Brinth, L. S., Pors, K., Theibel, A. C., and Mehlsen, J. (2015). Orthostatic intolerance
and postural tachycardia syndrome as suspected adverse effects of vaccination
against human papilloma virus. Vaccine 33, 2602–2605. doi: 10.1016/j.vaccine.
2015.03.098
Eeftinck Schattenkerk, D. W., Van Lieshout, J. J., Van Den Meiracker, A. H.,
Wesseling, K. R., Blanc, S., Wieling, W., et al. (2009). Nexfin noninvasive
continuous blood pressure validated against Riva-Rocci/Korotkoff. Am. J.
Hypertens. 22, 378–383. doi: 10.1038/ajh.2008.368
Fedorowski, A., Burri, P., Juul-Moller, S., and Melander, O. (2010). A dedicated
investigation unit improves management of syncopal attacks (Syncope Study
of Unselected Population in Malmo–SYSTEMA I). Europace 12, 1322–1328.
doi: 10.1093/europace/euq168
Fedorowski, A., Li, H., Yu, X., Koelsch, K. A., Harris, V. M., Liles, C., et al. (2017).
Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace 19,
1211–1219. doi: 10.1093/europace/euw154
Freeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I.,
et al. (2011). Consensus statement on the definition of orthostatic hypotension,
neurally mediated syncope and the postural tachycardia syndrome. Auton.
Neurosci. 161, 46–48. doi: 10.1016/j.autneu.2011.02.004
Goodman, B. P. (2018). Evaluation of postural tachycardia syndrome (POTS).
Auton. Neurosci. 215, 12–19. doi: 10.1016/j.autneu.2018.04.004
Grubb, B. P. (2008). Postural tachycardia syndrome. Circulation 117, 2814–2817.
doi: 10.1161/CIRCULATIONAHA.107.761643
Guimont, P., Grondin, F., and Dubois, C. M. (2007). Sox9-dependent
transcriptional regulation of the proprotein convertase furin.Am. J. Physiol. Cell
Physiol. 293, C172–C183. doi: 10.1152/ajpcell.00349.2006
Hastie, T., Tibshirani, R., and Friedman, J. (2013). The Elements of
Statistical Learning: Data Mining, Inference, and Prediction. New York,
NY: Springer.
Johansson, M., Ricci, F., Aung, N., Sutton, R., Melander, O., and Fedorowski, A.
(2018a). Inflammatory biomarker profiling in classical orthostatic hypotension:
insights from the SYSTEMA cohort. Int. J. Cardiol. 259, 192–197. doi: 10.1016/
j.ijcard.2017.12.020
Johansson, M., Ricci, F., Aung, N., Sutton, R., Melander, O., and Fedorowski, A.
(2018b). Proteomic profiling for cardiovascular biomarker discovery in
Frontiers in Neuroscience | www.frontiersin.org 6 March 2019 | Volume 13 | Article 301
fnins-13-00301 March 29, 2019 Time: 16:15 # 7
Spahic et al. Inflammatory Proteomics in POTS
orthostatic hypotension. Hypertension 71, 465–472. doi: 10.1161/HYPER
TENSIONAHA.117.10365
Li, H., Yu, X., Liles, C., Khan, M., Vanderlinde-Wood, M., Galloway, A., et al.
(2014). Autoimmune basis for postural tachycardia syndrome. J. Am. Heart
Assoc. 3:e000755. doi: 10.1161/JAHA.113.000755
Lin, H., Ah Kioon, M. D., Lalou, C., Larghero, J., Launay, J. M., Khatib, A. M., et al.
(2012). Protective role of systemic furin in immune response-induced arthritis.
Arthritis Rheum. 64, 2878–2886. doi: 10.1002/art.34523
Lisi, S., Sisto, M., Lofrumento, D. D., Cucci, L., Frassanito, M. A., Mitolo, V.,
et al. (2010). Pro-inflammatory role of Anti-Ro/SSA autoantibodies through
the activation of Furin-TACE-amphiregulin axis. J. Autoimmun. 35, 160–170.
doi: 10.1016/j.jaut.2010.06.020
Loetscher, H., Pan, Y. C., Lahm, H. W., Gentz, R., Brockhaus, M., Tabuchi, H.,
et al. (1990). Molecular cloning and expression of the human 55 kd
tumor necrosis factor receptor. Cell 61, 351–359. doi: 10.1016/0092-8674(90)
90815-V
Moya, A., Sutton, R., Ammirati, F., Blanc, J. J., Brignole, M., Dahm, J. B., et al.
(2009). Guidelines for the diagnosis and management of syncope (version
2009): the task force for the diagnosis and management of syncope of the
european society of cardiology (ESC). Eur. Heart J. 30, 2631–2671. doi: 10.1093/
eurheartj/ehp298
Pesu, M., Watford, W. T., Wei, L., Xu, L., Fuss, I., Strober, W., et al. (2008).
T-cell-expressed proprotein convertase furin is essential for maintenance
of peripheral immune tolerance. Nature 455, 246–250. doi: 10.1038/nature
07210
Piguet, V., Wan, L., Borel, C., Mangasarian, A., Demaurex, N., Thomas, G., et al.
(2000). HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate
class I major histocompatibility complexes. Nat. Cell. Biol. 2, 163–167. doi:
10.1038/35004038
Ranta, N., Valli, A., Gronholm, A., Silvennoinen, O., Isomaki, P., Pesu, M.,
et al. (2018). Proprotein convertase enzyme FURIN is upregulated in primary
Sjogren’s syndrome. Clin. Exp. Rheumatol. 36(Suppl. 112), 47–50.
Richards, R. M., Lowy, D. R., Schiller, J. T., and Day, P. M. (2006). Cleavage of the
papillomavirus minor capsid protein, L2, at a furin consensus site is necessary
for infection. Proc. Natl. Acad. Sci. U.S.A. 103, 1522–1527. doi: 10.1073/pnas.
0508815103
Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys. New York,
NY: John Wiley & Sons. doi: 10.1002/9780470316696
Ruzieh, M., Batizy, L., Dasa, O., Oostra, C., and Grubb, B. (2017). The role of
autoantibodies in the syndromes of orthostatic intolerance: a systematic review.
Scand. Cardiovasc. J. 51, 243–247. doi: 10.1080/14017431.2017.1355068
Sheldon, R. S., Grubb, B. P. II, Olshansky, B., Shen, W. K., Calkins, H., Brignole, M.,
et al. (2015). 2015 heart rhythm society expert consensus statement on the
diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus
tachycardia, and vasovagal syncope. Heart Rhythm. 12, e41–e63. doi: 10.1016/j.
hrthm.2015.03.029
Watari, M., Nakane, S., Mukaino, A., Nakajima, M., Mori, Y., Maeda, Y., et al.
(2018). Autoimmune postural orthostatic tachycardia syndrome. Ann. Clin.
Transl. Neurol. 5, 486–492. doi: 10.1002/acn3.524
Yu, X., Li, H., Murphy, T. A., Nuss, Z., Liles, J., Liles, C., et al. (2018). Angiotensin II
type 1 receptor autoantibodies in postural tachycardia syndrome. J. Am. Heart
Assoc. 7:e008351. doi: 10.1161/JAHA.117.008351
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Spahic, Ricci, Aung, Axelsson, Melander, Sutton, Hamrefors and
Fedorowski. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 7 March 2019 | Volume 13 | Article 301
